Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer

Ji Yan1, Shida Yang2, Hong Tian3, Yang Zhang4 and Hongmei Zhao2

Abstract
Colorectal cancer (CRC) is the type of cancer with the third highest incidence and is associated with high mortality and low 5-year survival rates. We observed that copanlisib, an inhibitor of PI3K (pan-class I phosphoinositide 3-kinase) that preferentially inhibits PI3Kδ and PI3Kα, impedes the growth of CRC cells by inducing apoptosis via PUMA. There was a marked increase in the expression of PUMA independent of p53 after treatment with copanlisib. The response of CRC cells to copanlisib could be predicted by PUMA expression. Copanlisib was found to induce PUMA expression through FoxO3a by directly binding to the PUMA promoter after inhibiting AKT signaling. PUMA deficiency mitigated the apoptosis induced by copanlisib. Caspase activation and mitochondrial dysfunction led to copanlisib resistance, as observed through a clonogenic assay, whereas enhanced expression of PUMA increased the copanlisib-induced susceptibility to apoptosis. Moreover, the antitumor effects of copanlisib were suppressed by a deficiency of PUMA in a xenograft model, and caspase activation and reduced apoptosis were also observed in vivo. Copanlisib-mediated chemosensitization seemed to involve the concurrent induction of PUMA expression via mechanisms that were both dependent and independent of p53. These observations indicate that apoptosis mediated by PUMA is crucial for the anticancer effects of copanlisib and that manipulation of PUMA may aid in enhancing anticancer activities.

Introduction
Clinically, colorectal cancer (CRC) is a frequently occurring and widely observed malignancy12. Worldwide, CRC is the third and second most common cancer in male and female patients, respectively, and its mortality rate is the fourth and third highest in these groups, respectively14. In the past 20 years, there have been annual increases in the incidence and mortality rates of CRC5,6. Although postoperative prevention and therapy has led to better CRC treatments, there has been no significant improvement in the 5-year survival rate of CRC7,8. Treatment of CRC faces the major challenge of tumor neovascularization, which often causes CRC metastasis and invasion of other organs9.

Copanlisib (also known as BAY 80-6946) is a pan-class I PI3K IV inhibitor with dominant activity toward PI3Kα and PI3Kδ10. Copanlisib has also exhibited preclinical antitumor activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL)11. The early demonstration of the clinical activity of copanlisib in FL and DLBCL was confirmed in phase 2 studies and extended to MZL, MCL, PTCL (peripheral T cell lymphoma), and small lymphocytic lymphoma12. The toxicity associated with copanlisib compares well with that associated with other agents of the same class, and copanlisib is associated with fewer and less severe gastrointestinal toxicities than idelalisib10,13. Copanlisib is now approved by the FDA for relapsed FL patients after at least
2 systemic therapies due to the results of a phase 2 study showing an ORR of 59% and a CR of 14%. PUMA (p53-upregulated modulator of apoptosis) is a member of the family of BH3-only Bcl-2 proteins and a strong inducer of apoptosis. In response to the DNA damage caused by gamma radiation and common chemotherapy drugs, p53 activates the transcription of PUMA. PUMA causes permeabilization of the mitochondrial membrane, subsequent activation of the caspase cascade by binding to each of the five members of the pro-apoptotic Bcl-2 family, including Bcl-2 and Bcl-XL, and release of Bax and Bak inhibition. PUMA knockout causes resistance to the genotoxic agent-induced, p53-dependent apoptosis in human cancer cells and mice. However, abnormalities of p53 cause dysfunctional p53-dependent regulation of PUMA in most cancer cells, leading to tumor cell survival and resistance to treatment. PUMA-mediated apoptosis that is independent of p53 is induced by several types of stimuli that are non-genotoxic, including serum starvation, ischemia/reperfusion, glucocorticoids, and TNF-α. Various transcription factors, including p65, Forkhead Box O3a (FoxO3a), and p73, have been indicated in PUMA-mediated, p53-independent induction of apoptosis.

In this study, we examined the mechanism by which copanlisib induces PUMA and its function in chemosensitization and apoptosis. We further assessed the roles of FoxO3a and PUMA in the anticancer activity of copanlisib. The results present new insights into the mechanism of the response to copanlisib treatment, with potentially broad implications for future applications.

### Materials and methods

#### Cell culture and treatment

Human colorectal cancer cell lines (DLD1, HCT116, HT29, RKO, Lim2405, SW620, SW837, Lim1215, HCT-8, SW48, SW480, SW1463, HCT15, and LoVo) were obtained from ATCC (Manassas, VA). The status of PIK3CA, PIK3R1, and p53 in the cell lines mentioned above is listed in Table 1. The CRISPR/Cas9 system was used to generate p53-KO (knockout) and PUMA-KO HCT116 cells. Each cell line was cultured in modified McCoy’s 5A media from Invitrogen (Carlsbad, CA) containing 10% FBS from HyClone (Logan, UT), one hundred units per milliliter penicillin, and one hundred micrograms per milliliter streptomycin from Invitrogen. NCM356 and NCM460 cells were procured from INCELL and grown in the provided enriched M3 base medium (M310A; INCELL) supplemented with 5% FBS and antibiotics in a 37 °C incubator with 5% CO₂. All of the cell lines listed above were authenticated by short tandem repeat profiling and were routinely tested for mycoplasma contamination. Twenty-four hours before drug treatment, cells (20–30% density) were added to 12-well plates. The reagent stocks of copanlisib, 5-FU, and regorafenib in dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO) were diluted to the required concentrations in the media used for cell culture.

#### Knockout cell line generation with CRISPR/Cas9

The website for CRISPR design (http://crispr.mit.edu/), provided by the Feng Zhang Lab, was used to design the CRISPR/Cas9 guide RNA (gRNA) sequences. The oligonucleotides complementary for the FoxO3a or PUMA gRNA were cloned after annealing into the pX459 CRISPR/Cas9-Puro vector from Addgene (Cambridge, MA). The transfection of DLD1 and HCT116 cells was performed with either pX459/gRNA-FoxO3a or pX459/gRNA-PUMA using Lipofectamine 2000, as per the provided instructions. Twenty-four hours posttransfection, the cells were treated with puromycin (2 μg/mL) for 72 h. After 14 days, the isolation of colonies using cloning cylinders was performed, and the analysis of the FoxO3a or PUMA sequences was performed with a T7E1 (T7 endonuclease) assay and western blotting.

#### MTS assay

Cells were seeded (1 x 10⁴ cells per well) in 96-well plates and treated with different agents for 3 days. Cell viability was evaluated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega) according to the provided instructions. Chemiluminescence was measured using Perkin Elmer’s Wallac Victor 1420 Multilabel Counter. All the assays were carried out in triplicate and repeated three times.

---

### Table 1 Genes mutations in CRC cell lines.

| Cell line | PIK3CA | PIK3R1 | p53 |
|-----------|--------|--------|-----|
| HCT116    | Mut    | WT     | WT  |
| DLD1      | Mut    | WT     | WT  |
| SW1463    | WT     | WT     | Mut |
| Lim1215   | WT     | WT     | WT  |
| HCT15     | Mut    | WT     | WT  |
| HT29      | Mut    | WT     | WT  |
| RKO       | Mut    | WT     | WT  |
| Lim2405   | WT     | WT     | WT  |
| SW620     | WT     | WT     | Mut |
| SW48      | Mut    | WT     | WT  |
| SW480     | WT     | WT     | Mut |
| LoVo      | WT     | WT     | Mut |
| SW837     | WT     | WT     | Mut |
| HCT-8     | Mut    | WT     | WT  |
Western blotting

Western blotting was performed as described in a previous study. The extraction of the total proteins from cells was carried out using a Nuclear and Cytoplasmic Protein Extraction kit, and the protein concentration was determined with an Enhanced BCA Protein Assay kit. The lysates were diluted to 5 μg/μL, and a ten percent SDS-PAGE gel was used to resolve 60 μg of each of the protein samples. The proteins were transferred to membranes made of PVDF from EMD Millipore at 135 mA and 100 mV on a Bio-Rad Trans-Blot from Bio-Rad Laboratories, Inc. After blocking the membranes in five percent skim milk at room temperature for 60 min, the membranes were incubated in 5% BSA solution containing primary antibodies at 4 °C overnight. Then, after washing the membranes four times with TBS-Tween for 10 min each, the membranes were incubated at room temperature with secondary horseradish peroxidase (HRP)-conjugated antibodies for 60 min. The membranes were washed with TBS-Tween six times, and the signals were visualized using an ECL reagent from EMD Millipore on X-ray films. The primary antibodies were as follows: cleaved caspase-3 (#9661, Cell Signaling Technology), cleaved caspase 8 (#9748, Cell Signaling Technology), cleaved caspase-9 (#9505, Cell Signaling Technology), PUMA (#4976, Cell Signaling Technology), Bim (#2819, Cell Signaling Technology), Mcl-1 (#4572, Cell Signaling Technology), Bid (#2002, Cell Signaling Technology), Bax (#2772, Cell Signaling Technology), Bcl-xL (#2764, Cell Signaling Technology), Bcl-2 (#4223, Cell Signaling Technology), p-AKT (#4060, Cell Signaling Technology), AKT (#9272, Cell Signaling Technology), p-mTOR (#2974, Cell Signaling Technology), mTOR (#2972, Cell Signaling Technology), cytochrome c (#4272, Cell Signaling Technology), Noxa (sc-515840, Santa Cruz Biotechnology), Cox IV (ab14744, Abcam), FoxO3a (ab109629, Abcam), FoxO3a (ab240127, Abcam), and β-actin (A5441, Sigma).

Real-time reverse transcriptase (RT) PCR

Real-time PCR was performed as previously described. Total RNA was isolated using the Mini RNA Isolation II Kit from Zymo Research (Orange, CA) according to the provided instructions. One microgram of total RNA was used to synthesize cDNA using Invitrogen’s SuperScript II reverse transcriptase. Real-time PCR for PUMA and GAPDH was conducted as previously described.

Cell transfection and knockdown using siRNA

The transfection of cells with Lipofectamine 3000 from Invitrogen was carried out according to the manufacturer’s instructions. Vectors constitutively expressing FoxO3aTM (FoxO3a triple mutant; Addgene), pCMV, WT, and AKT were transfected as specified. One day prior to copanlisib treatment, siRNA knockdown was carried out using FoxO3a-specific siRNA (400 pmol) or the scrambled, control siRNA from Dharmacon.

Mitochondrial membrane potential (MMP) assay

The MMP was analyzed by JC-1 staining according to the manufacturer’s instructions. Briefly, WT or PUMA-KO HCT116 cells were seeded in 12-well plates and treated with copanlisib for 24 h. The cells were then washed with PBS and suspended in fresh medium. The cells were then incubated with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1) staining solution (5 μM) at 37°C and 5% CO2 for 20 min. After washing with PBS, the fluorescence intensity was visualized using a confocal microscope (Carl Zeiss, Germany). The red/green fluorescence intensity ratio was analyzed by the Imagej software.

Luciferase activity assay

A genomic wild-type (WT) fragment of the first intron of PUMA containing two FoxO3a sites was cloned into the pBVLuc vector to generate the PUMA luciferase reporter construct as previously described. Next, the site-directed mutagenesis QuickChange XL kit (Stratagene, USA) was used to introduce mutations into the FoxO3a binding sites. To assess the reporter activity, cells were transfected with the reporter harboring WT or mutant PUMA along with the β-galactosidase reporter pCMVβ (Promega, Madison, WI, USA) as the transfection control. The luciferase activity was measured after collecting the cell lysates. Each reporter assay was carried out in triplicate and repeated three times.

Chromatin immunoprecipitation (ChIP)

ChIP was performed using the ChIP Assay kit from Upstate Biotechnology (Lake Placid, NY, USA) as previously described, using an antibody against FoxO3a. Analysis of the precipitates was performed through PCR using the following primers: 5′-TGGGTGTGGCCTCGGC-3′ and 5′-GCGCACAGGTGCCTCGGC-3′.

Apoptosis

Apoptosis was detected by staining the nuclei with Hoechst 33342 from Invitrogen as previously described. Staining with propidium iodide (PI)/Annexin V was carried out using PI and annexin Alexa 488 from Invitrogen according to the instructions. To analyze the release of cytochrome c, the cytosolic and mitochondrial fractions were isolated by differential centrifugation as instructed and probed for cytochrome c by western blotting. In the colony formation assay, the treated cells were seeded in plates (12-well) at the indicated dilutions, grown for 10–14 days, and then stained with crystal violet from Sigma.
PDX mouse model

Nu/Nu mice (5–6 weeks old, female; Charles River) and NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, 4–6 weeks old, Jackson Laboratory) were placed in cages (micro isolator) in a sterile environment and were given access to chow, and water ad libitum. Two PDX models were established using primary tumors resected from treatment-naïve, newly diagnosed CRC patients. The patients provided written informed consent, and the study was approved by the IRB. The tumors were subcutaneously implanted and passaged. Briefly, de-identified patient CRC samples were delivered to the laboratory in 1× Antibiotic/Antimycotic solution (Invitrogen) within 4 h after tumor resection. The tissues were cut into 25-mg pieces and directly implanted subcutaneously into both flanks of NSG mice. Tumors passedaged and expanded for two generations (P3) in NSG mice were used for the described experiments. The mice were randomly divided into two groups, and no blinding was performed. Treatment was carried out for 20 days following the procedure for cell line xenografts (n = 6 mice per group). Using calipers, the growth of the tumors was measured, and the volumes were determined using the formula 1/2 × length × width². The definition of the ethical endpoint was the time point when the dimension of a tumor was 1.5 cm or more on any side. After dissection, the tumors were formalin-fixed (10%) and paraffin-embedded. Immunostaining was performed using TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) from EMD Millipore and active caspase-3 antibodies from Cell Signaling Technology. The tumor sections (paraffin-embedded, 5 μm) described above were incubated with secondary antibodies (AlexaFluor 488-conjugated; Invitrogen) for detection and DAPI (4′,6-diamidino-2-phenylindole) to counterstain the nucleus.

Xenograft studies

The mice described above were subcutaneously injected with WT or PUMA-KO HCT116 cells (4 × 10⁶ cells) in both flanks. After seven days of tumor growth, the mice were randomly divided into two groups, and no blinding was performed. Intraperitoneal (i.p.) injections of copanlisib (30 mg/kg) were administered for ten consecutive days. For combination studies, the mice were randomly divided into four groups, and no blinding was performed. I.p. injections of 10 mg/kg copanlisib and 25 mg/kg 5-FU
APP Pharmaceuticals, Schaumburg, IL) were administered every other day or together for 10 consecutive days. The tumor growth and volumes were estimated as described in the previous section. After euthanizing the mice when the tumor volumes reached ~1 cm³, the same procedure for fixation, labeling, immunostaining, and visualization was followed as described in the previous section.

**Statistical analysis**

For this analysis, GraphPad Prism IV software was used. P-values were determined by Student’s t-test, and a value <0.05 was deemed significant. The mean ± one SD (standard deviation) is presented in the figures.

**Results**

Copanlisib promotes growth inhibition and apoptosis in CRC cells

To investigate the effect of copanlisib on CRC cells, we first examined the viability of the CRC cells treated for 72 h with increasing concentrations of copanlisib. The MTS results demonstrated that copanlisib inhibits CRC cell proliferation (Fig. 1A). An in vitro assay was used to ensure the safety of the tested concentrations, and copanlisib toxicity was examined in human NCM356 and NCM460 cells. However, after the treatment of these cells with similar concentrations of copanlisib, there was no major difference in its effects on cell viability (Fig. 1A). It was clear from the data that copanlisib had no effect on...
nontransformed cells but had a selective inhibitory effect on CRC cells. The pro-apoptotic effect of copanlisib was examined using a nuclear fragmentation assay. Our results showed that copanlisib treatment significantly increased the apoptotic rates of DLD1 and HCT116 cells (Fig. 1B). Consequently, to prove that cell death was the result of caspase-dependent apoptosis, we pretreated the cells with z-VAD-fmk, a pan-caspase inhibitor. Our findings demonstrated that the pro-apoptotic effects of copanlisib on the DLD1 cells and HCT116 cells were reversed by the pan-caspase inhibitor z-VAD-fmk (Fig. 1C). Subsequently, treatment with copanlisib increased the levels of cleaved caspase-3, -8, and -9 (Fig. 1D).

Therefore, our results indicate that copanlisib-induced caspase-dependent apoptosis in CRC cells.

**PUMA expression is induced by copanlisib in a p53-independent manner**

Next, we evaluated the impact of copanlisib on proteins of the Bcl-2 family and observed the induction of PUMA after treatment with copanlisib (Figs. 2A and Supplementary Fig. S1A). In both WT and p53-depleted HCT116 cells, copanlisib-induced PUMA upregulation in a time-dependent manner (Fig. 2B). However, the lack of p53 slightly delayed the copanlisib-induced PUMA induction (Fig. 2B). Furthermore, we observed the peak

---

**Fig. 3 PUMA-mediated copanlisib-induced apoptosis.** A WT and PUMA-KO HCT116 cells were treated with copanlisib at indicated concentrations for 24 h. Apoptosis was analyzed by nuclear fragmentation assay. B WT and PUMA-KO DLD1 cells were treated with copanlisib at indicated concentrations for 24 h. Apoptosis was analyzed by nuclear fragmentation assay. C WT and PUMA-KO HCT116 or DLD1 cells were treated with 100 nM copanlisib for 24 h. Apoptosis was analyzed by flow cytometry. D WT and PUMA-KO HCT116 cells were treated with 100 nM copanlisib for 24 h. The indicated protein level was analyzed by western blotting. E Cytosolic fractions isolated from WT and PUMA-KO HCT116 cells treated with 100 nM copanlisib for 24 h were probed for cytochrome c by western blotting. β-actin and cytochrome oxidase subunit IV (Cox IV), which are expressed in cytoplasm and mitochondria, respectively, were analyzed as the control for loading and fractionation. F Colony formation of WT and PUMA-KO HCT116 cells treated with 100 nM copanlisib for 48 h following crystal violet staining of attached cells at 14 days. Left, representative pictures of colonies; Right, quantification of colony numbers. Results in A–C and F were expressed as means ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 4 (See legend on next page.)
level of PUMA mRNA induction within eight hours and that of PUMA protein induction within 24 h of copanlisib treatment (Fig. 2C). This induction could be attenuated by actinomycin D, a transcription inhibitor (Fig. 2D). These results indicate that PUMA expression is induced by copanlisib through a transcription mechanism that is independent of p53. A correlation between copanlisib-mediated PUMA induction and apoptosis was also revealed in 12 CRC cell lines (Fig. 2E). After treatment, the cell lines with endogenously low PUMA expression but strongly induced PUMA expression exhibited high apoptotic levels, while the cell lines with little or no induction of PUMA expression had barely detectable or low levels of apoptosis (Fig. 2F). Therefore, PUMA expression selectively induced by copanlisib treatment enhances apoptosis in CRC cells.

**PUMA is required for copanlisib-induced apoptosis**

We examined the effect of copanlisib on PUMA-KO HCT116 cells. Apoptosis was observed in WT cells in a dose-dependent manner, with over 30% apoptotic cells after 100 nM copanlisib treatment (Fig. 3A). Remarkably, the apoptosis induced by copanlisib was nearly absolutely abolished in PUMA-KO cells (Fig. 3A). Such a requirement for PUMA was not cell line-specific, as copanlisib prevented the apoptosis of the previously described PUMA-KO DLD1 CRC cells (Fig. 3B). This decline in apoptosis in PUMA-deficient cells was confirmed by further analysis using annexin V/PI staining (Fig. 3C). The deficiency in PUMA attenuated copanlisib-induced caspase-9 and -3 activation (Fig. 3D). Interestingly, a higher baseline level of cleaved caspase-9 was observed in the PUMA-KO HCT116 cells (Fig. 3D). We also found that PUMA depletion blocked the copanlisib-mediated cytochrome c release into the cytosol in HCT116 cells (Fig. 3E). To investigate the role of mitochondrial dysfunction in copanlisib-induced apoptosis, we analyzed the loss of the ΔΨm in the copanlisib-treated WT and PUMA-KO HCT116 cells by JC-1 staining. Our results indicated that the copanlisib-induced loss of the ΔΨm was absent in the PUMA-KO cells (Supplementary Fig. S2A, B). In addition, in a long-term clonogenic assay, significantly enhanced resistance to copanlisib was observed in the PUMA-deficient cells compared with the WT cells (Fig. 3F). Hence, these results suggest the necessity of PUMA for the induction of apoptosis by copanlisib in CRC cells.

**Activation of PUMA transcription by FoxO3a after copanlisib treatment**

FoxO3a, a transcription factor, can induce PUMA expression in mast cells and T cells after cytokine deprivation35. Copanlisib has been implicated in AKT inhibition36, which leads to FoxO3a phosphorylation and arrests its nuclear localization; therefore, we assessed the roles of FoxO3a and AKT in copanlisib-mediated induction of PUMA expression. We observed that in the p53-KO cells, the expression of FoxO3aTM, a constitutively active mutant of FoxO3a, induced PUMA upregulation (Fig. 4A). In the WT and p53-KO HCT116 cells, siRNA-mediated depletion of FoxO3a abrogated the copanlisib-mediated induction of PUMA (Fig. 4B), indicating that FoxO3a is required for PUMA induction following kinase inhibition.

The mouse and human PUMA promoters possess a conserved FoxO binding element (AAACA)37. We noted that in addition to this site, two bases apart, another FoxO3a binding element exists in the reverse orientation in the first intron of PUMA (Fig. 4C). To examine the role of these binding sites in the induction of PUMA expression, a 1.1-kb fragment harboring these two sites was cloned along with luciferase reporters and analyzed. Furthermore, the mutation of these binding sites was also carried out to determine their precise function in the induction of PUMA expression (Fig. 4C). FoxO3aTM
transfection or copanlisib treatment of cells led to remarkable activation of the WT PUMA reporter. In comparison, the mutations in the binding sites eliminated the responsiveness of the PUMA reporter to FoxO3a and abolished the effects of copanlisib (Fig. 4D, E). In the ChIP assay, we observed that the binding of FoxO3a to the PUMA promoter was markedly increased following treatment with any one of the agents (Fig. 4F). Thus, according to the abovementioned results, the direct binding of FoxO3a to the PUMA promoter activates its transcription after treatment with copanlisib.

Inhibition of AKT drives induction of PUMA by copanlisib

Then, we examined the effect of copanlisib on PUMA expression, and the role of AKT, an antiapoptotic kinase that is characterized by abnormal activation in cancer cells. Treatment with copanlisib markedly inhibited the phosphorylation of AKT at S473; this effect was concurrent with the decreased phosphorylation of FoxO3a (Fig. 4G), which prevented its nuclear translocation and subsequent transactivation. In contrast, phosphorylation of FoxO3a by the transfection of either WT or constitutively active AKT suppressed the baseline expression of PUMA (Fig. 4H) and limited the induction of PUMA by copanlisib (Fig. 4I). In addition, the siRNA-mediated transient knockdown of FoxO3a led to the suppression of the PUMA induction and apoptosis induced by copanlisib (Fig. 4J). Thus, PUMA induction by FoxO3a after treatment with copanlisib was possibly mediated via inhibition of AKT.

Suppression of PDX model growth by copanlisib

For in vivo examination of the effects of copanlisib, we used PDX models, which mimic the histopathology and heterogeneity of patient tumors and have been used to predict clinical responses of patients to particular drugs. Mice harboring PDX1 tumors were arbitrarily grouped and subjected to daily treatment with either copanlisib or
vehicle control. Potent inhibition of PDX1 tumor growth and an increase in survival time of the tumor-bearing mice due to copanlisib were observed (Fig. 5A, B). Analyses of the RNA and protein from the tumor tissues confirmed the induction of PUMA by copanlisib (Fig. 5C, D). Furthermore, an enhanced number of TUNEL-positive cells and enhanced staining of cleaved caspase-3 after 20 days of treatment were observed (Fig. 5E, F). In addition, there was a similar response of PDX2 tumors to copanlisib (Supplementary Fig. S3A–F). Thus, copanlisib promoted apoptosis and impaired proliferation. Upon treatment of the tumor-bearing mice with copanlisib, there was no significant change in body weight change, and the mice did not show any obvious signs of toxicity (Fig. 5G and Supplementary Fig. S3G).

The antitumor activity of copanlisib in a xenograft model is supported by PUMA

To study the mechanism, nude mice were injected with WT or PUMA-KO HCT116 cells to establish a tumor xenograft model, and these mice were then treated with copanlisib for 5 days. The assessments were performed as described in the methods section. WT tumors responded to the treatment by exhibiting slower growth, and the size of the treated tumors was nearly 20% that of the untreated tumors on day 22 (Fig. 6A). In contrast, PUMA-KO tumors were less sensitive to copanlisib treatment (Fig. 6A). Furthermore, phosphorylation of AKT and FoxO3a was suppressed after treatment (Fig. 6B), and the expression of PUMA was induced in the WT tumors (Fig. 6B). There was a significant induction of apoptosis in the WT tumors, and TUNEL and active caspase-3 staining revealed that this induction was nearly absolutely abolished in the PUMA-KO tumors (Fig. 6C, D). Therefore, PUMA is an important factor for the in vivo apoptotic and antitumor effects of copanlisib.

Chemosensitization effects of copanlisib are mediated by PUMA

Copanlisib is generally combined with conventional cytotoxic treatments for cancer. We hypothesized that the chemosensitization to copanlisib is mediated by PUMA induction due to the obvious activation of PUMA by copanlisib and other drugs. In particular, robust synergetic effects of copanlisib and 5-FU or regorafenib in HCT116 cells were observed (Fig. 7A–D). We further validated these findings in the DLD1 cell line (Supplementary Fig. S4A–D). Indeed, copanlisib in association with 5-FU induced PUMA to a level much higher than that induced by 5-FU or copanlisib alone (Fig. 7E). This is consistent with PUMA induction through pathways that are both dependent and independent of p53. Therefore, after the combination treatment, the WT HCT116 cells exhibited a significantly higher degree of apoptosis, but similar results were not observed in PUMA-KO cells (Fig. 7G). Copanlisib combined with regorafenib, which induces PUMA expression through the GSK-3β/NF-kB-mediated pathway, also revealed an increased induction of apoptosis that was dependent on PUMA (Fig. 7F, H). Therefore, the data suggest that PUMA regulates apoptosis by mediating the chemosensitization activity of copanlisib and thus enhances the therapeutic efficacy of copanlisib.

The same outcomes were observed in vivo when nude mice bearing WT or PUMA-KO HCT116 xenograft tumors were treated with copanlisib (10 mg/kg), 5-FU (25 mg/kg), or the combination. The growth of the WT tumors was more effectively suppressed by the combination treatment than with either the copanlisib or 5-FU treatment alone (Fig. 7I). However, this enhanced tumor suppression was significantly abolished in the PUMA-KO tumors (Fig. 7I), which also correlated with a decline in apoptosis as detected by active caspase-3 staining (Fig. 7J) and TUNEL staining (Fig. 7K). Thus, in the in vitro and in vivo chemosensitization effects of copanlisib are mediated by PUMA, and further manipulation may enhance the treatment efficacy of copanlisib.

Discussion

The observations of this study provide insight into the mechanism of the anticancer activity of copanlisib. Several previous studies have examined the effects of copanlisib on cell cycle checkpoints, which are generally considered to be the primary mode of action in the treatment of cancer. Reports also suggest that copanlisib potentiates apoptosis through the mitochondrial pathway, although the precise mechanism of action is still unclear, and the status of apoptosis as a response to copanlisib treatment remains a speculation. The results of our study show, for the first time, that copanlisib causes the induction of PUMA by FoxO3a after inhibition of AKT. PUMA induction contributes to most, if not all, of the observed in vivo and in vitro effects of copanlisib against CRC cells, and this role of PUMA was independent of the p53 status and genetic background. In addition to PUMA, other proteins of the BH3-only family, such as Bim, may participate in the effect of copanlisib on other types of tumors.

PUMA, a member of the BH3-only Bcl-2 family, can be induced by other apoptotic signals or p53. When overexpressed in various cell lines, PUMA induces cell death by associating with the mitochondria, and an important requisite of its apoptotic activity is an intact BH3 domain. These studies, and the findings from a tumor cell line with a somatic knockout, indicate an important role of PUMA as an in vivo apoptotic regulator. PUMA has been indicated to participate in the important processes of tumorigenesis. PUMA may be a possible target
for chemotherapy, as activation of PUMA inhibits the growth of tumors by reinitiating apoptosis in cancer cells. The induction of PUMA is possible in a manner that is independent of p53. In nongenotoxic stimulations, such as growth factor deprivation, inflammatory cytokines, and kinase inhibitors, the p53-independent induction of PUMA can be mediated by transcription factors, such as FoxO3a, E2F1, NF-κB, and p73. After its induction in cancer cells, PUMA causes high rates of apoptosis by acting on other proteins, such as Bax and Bcl-2 of the Bcl-2 family, and triggers the caspase cascade. In this study, we observed a marked induction of PUMA expression by copanlisib in a time- and dose-dependent manner in p53-null cells and WT cells. Subsequently, the ratio of Bax/Bcl-2 increased due to copanlisib. The cytotoxic effect of copanlisib was attenuated by knockdown of PUMA using specific siRNAs, indicating the possible association of the function of copanlisib with the p53-independent induction of PUMA.

There are few recent reports on the FoxO3a-mediated induction of PUMA via suppression of the PI3K/AKT signaling pathway. For instance, sunitinib, a multikinase inhibitor, can induce the transcription of PUMA in human colorectal cancer through the AKT/FoxO3a axis. In response to the deprivation of cytokines or growth factors, PUMA expression is directly upregulated by FoxO3a when PI3K/AKT signaling is blocked. AKT activation can be suppressed by copanlisib; hence, it is

**Fig. 6 The antitumor effects of copanlisib in vivo are PUMA-dependent.** A) Nude mice were injected s.c. with 5 × 10^6 WT or PUMA-KO HCT116 cells. After 7 days, mice were treated with 30 mg/kg copanlisib or the vehicle control for 10 consecutive days. Tumor volume at indicated time points after treatment was calculated and plotted with P-values, n = 6 in each group. B) Mice with WT HCT116 xenograft tumors were treated with 30 mg/kg regorafenib or the vehicle as in A for four consecutive days. The indicated protein level was analyzed by western blotting. C) Paraffin-embedded sections of WT or PUMA-KO tumor tissues from mice treated as in B were analyzed by active caspase-3 staining. Upper, representative staining pictures; lower, active caspase-3-positive cells were counted and plotted. Scale bars: 25 μm. D) Tissue sections from B were analyzed by TUNEL staining. Upper, representative TUNEL staining pictures; lower, TUNEL-positive cells were counted and plotted. Scale bars: 25 μm. Results in C and D were expressed as means ± SD of three independent experiments. **P < 0.01.
Fig. 7 PUMA mediates the chemosensitization effects of copanlisib in vitro and in vivo. A HCT116 cells treated with copanlisib, 5-FU, or their combination at indicated concentrations. The viability of cells was analyzed by the MTS assay. B Combination index was calculated form (A). C HCT116 cells treated with copanlisib, Regorafenib, or their combination at indicated concentrations. The viability of cells was analyzed by the MTS assay. D Combination index was calculated form (C). E HCT116 was treated with 10 nM copanlisib, 5 μg/mL 5-FU, or their combination for 24 h. The indicated protein level was analyzed by western blotting. F HCT116 were treated with 10 nM copanlisib, 0.5 μM Regorafenib, or their combination for 24 h. The indicated protein level was analyzed by western blotting. G WT and PUMA-KO HCT116 were treated with 10 nM copanlisib, 5 μg/mL 5-FU, or their combination for 24 h. Apoptosis was analyzed by nuclear fragmentation assay. H WT and PUMA-KO HCT116 were treated with 10 nM copanlisib, 0.5 μM Regorafenib, or their combination for 24 h. Apoptosis was analyzed by nuclear fragmentation assay. I Nude mice were injected s.c. with 5 × 10⁶ WT or PUMA-KO HCT116 cells. After 7 days, mice were treated with 10 mg/kg copanlisib daily, 25 mg/kg 5-FU every other day by i.p. injection, or their combination for ten consecutive days. Tumor volume at indicated time points after treatment was calculated and plotted. J Mice with WT or PUMA-KO HCT116 xenograft tumors were treated with 10 mg/kg regorafenib daily, 25 mg/kg 5-FU every other day, or their combination as in I for four consecutive days. Paraffin-embedded sections were analyzed by active caspase-3 staining. Active caspase-3-positive cells were counted and plotted. K Tissue sections from (I) were analyzed by TUNEL staining. TUNEL-positive cells were counted and plotted. Results in G-I and K were expressed as means ± SD of three independent experiments. **P < 0.01.
probable that the inhibition of AKT/FoxO3a signaling by copanlisib may cause the induction of PUMA. Concurrent FoxO3a knockdown weakened the effect of copanlisib on the induction of PUMA. Therefore, the inhibition of AKT/FoxO3a signaling may participate in the copanlisib-mediated, p53-independent induction of PUMA.

The dose of copanlisib used in this study is similar to that used in earlier studies on apoptosis. Our results indicate the potential role of PUMA induction in chemosensitization by copanlisib. Thus, combinations of different classes of PUMA-inducing agents may facilitate the simultaneous induction of PUMA through multiple pathways, causing a decline in the threshold of pro-apoptotic activity needed for the initiation of apoptosis. A potentially novel approach for cancer treatment involves targeting molecular changes that are specific to cancer. PUMA expression can be induced by inhibitors of EGFR, such as erlotinib and gefitinib, that are already used clinically in cancer of the head and neck, and expression of PUMA correlates with treatment response to the inhibitors of EGFR. Thus, PUMA may have an elaborate functional role in influencing responses to targeted treatments, and PUMA induction may have the role of a predictive marker of treatment response to these agents.

Tumor phenotypes depend on the suppression of apoptosis by specific proteins needed for survival because of the triggered apoptosis in response to neoplastic transformation. An interesting approach for cancer treatment may exploit the ability to reactivate apoptotic induction in cancer cells. Thus, apoptosis has emerged as a critical endpoint of copanlisib treatment. PUMA induction by copanlisib occurs primarily via mechanisms independent of p53. Such induction surpasses the network of p53, which is necessary for the effectiveness of common chemotherapeutic agents. In another approach, bypassing the p53 pathway would involve using agents that directly target the apoptosis machinery.

In summary, we found that PUMA is an important mediator of the treatment response to copanlisib in CRC cells. This study may lay a foundation for targeting the PUMA-enhanced effects of copanlisib treatment, using PUMA as a biomarker to predict therapeutic response, and for the logical design of new treatment regimens.

Author details
1 Department of Medicine Laboratory, The 4th People’s Hospital of Shenyang, Shenyang, Liaoning, China. 2 Department of Laboratory Medicine, The People’s Hospital of China Medical University (The People’s Hospital of Liaoning Province), Shenyang, Liaoning, China. 3 Oncology Department, The 4th People’s Hospital of Shenyang, Shenyang, Liaoning, China. 4 Department of Pathology, The 4th People’s Hospital of Shenyang, Shenyang, Liaoning, China

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-020-03154-w).

Received: 30 May 2020 Revised: 13 October 2020 Accepted: 15 October 2020 Published online: 02 November 2020

References
1. Krockenbein, K. et al. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37, 4599–4610 (2018).
2. Ibrahim, T. et al. Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. Ann. Saudi Med 38, 251–259 (2018).
3. Adhikari, S. et al. Clinical, pathological, and molecular characteristics of CpG island methylator phenotype (CIMP) colorectal cancer: a systematic review and meta-analysis. Transl. Oncol. 11, 1188–1201 (2018).
4. Stintzing, S. Recent advances in understanding colorectal cancer. F1000Res 7, F1000 Faculty Rev-1528 (2018).
5. Gardiello, D. et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat. Rev. 76, 22–32 (2019).
6. Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361–375 (2019).
7. Xie, Y. H., Chen, Y. X. & Fang, J. Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 5, 22 (2020).
8. Mostedt, D. P., Pant, S. & Santore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer 109, 70–83 (2019).
9. Wainberg, Z. A. & Drake, A. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationale for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. Expert Opin. Biol. Ther. 15, 1205–1220 (2015).
10. Mensah, F. A., Blazej, J. P. & Bryan, L. J. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 11, 4817–4827 (2018).
11. Krause, G., Hasenruck, F. & Halak, M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des. Dev. Ther. 12, 2577–2590 (2018).
12. Okabe, S., Tauchi, T., Taniaka, Y., Sakuta, J. & Ohyashiki, K. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells. OncoTARGET 7, 53116–53126 (2016).
13. Dreyling, M. et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann. Oncol. 28, 2169–2178 (2017).
14. Kumar, A. et al. Copanlisib: novel PI3K inhibitor for treatment of lymphoma. Anticancer Agents Med. Chem. 20, 1158–1172 (2020).
15. Yu, J. & Zhang, L. No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4, 248–249 (2003).
16. Yu, J., Wang, Z., Kindler, K. W., Vogelstein, B. & Zhang, L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl Acad. Sci. USA 100, 1931–1936 (2003).
17. Hikisz, P. & Kilianska, Z. M. PUMA, a critical mediator of cell death and death from its discovery. Cell Mol. Biol. Lett. 17, 646–669 (2012).
18. Qu, W. et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J. Clin. Invest. 121, 1722–1732 (2011).
19. Yu, H. et al. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-radiation. Blood 115, 3472–3480 (2010).
20. Li, L., Lin, L., Li, M. & Li, W. Gilteritinib induces PUMA-dependent apoptotic cell death via AKT/GSK-3beta/NF-kappaB pathway in colorectal cancer cells. J. Cell Mol. Med. 24, 2306–2318 (2020).
21. Lee, S. H. et al. Novel tumor suppressive function of Smad4 in serum starvation-induced cell death through PAK1-PUMA pathway. Cell Death Dis. 2, e235 (2011).
22. Tott, A. et al. Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol. 291, H52–H60 (2006).
23. Akhtar, R. S. et al. BRH-only proapoptotic Bcl-2 family members Nova and Puma mediate neural precursor cell death. J. Neurosci. 26, 7257–7264 (2006).
24. Obexer, P. et al. p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2. J. Biol. Chem. 284, 30933–30940 (2009).
25. Wang, P. et al. PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ. 16, 1192–1202 (2009).
26. Yang, S. et al. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3beta/NF-kappaB signaling pathway. Cancer Gene Ther. 27, 368–377 (2020).
27. Lin, L., Ding, D., Jiang, Y., Li, Y. & Li, S. MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells. Oncogenesis 7, 67 (2018).
28. Sun, Q. et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 28, 2348–2357 (2009).
29. Tong, J. et al. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 77, 2512–2521 (2017).
30. Tong, J. et al. Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BHS-only proteins. Cancer Res. 78, 4704–4715 (2018).
31. Tong, J., Tan, S., Zou, F., Yu, J. & Zhang, L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 36, 787–796 (2017).
32. Tong, J. et al. FBW7-dependent Mcl-1 degradation mediates the anticancer effect of His90 inhibitors. Mol. Cancer Ther. 16, 1979–1988 (2017).
33. He, K. et al. BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget 7, 47699–47710 (2016).
34. Chen, D. et al. PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc. Natl Acad. Sci. USA 113, 3990–3995 (2018).
35. Tzelepis, F. et al. Intrinsic role of FoxO3a in the development of CD8+ T cell memory. J. Immunol. 190, 1066–1075 (2013).
36. Okabe, S., Tanaka, Y., Tsuchi, T. & Ohyaishi, K. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation. Ann. Hematol. 98, 723–733 (2019).
37. Barthel, A., Schmoll, D. & Unterman, T. G. FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16, 183–189 (2005).
38. Ramanathan, R. K. et al. Phase Ib trial of the PI3K inhibitor copanlisib combined with the allosteric MEK inhibitor refametinib in patients with advanced cancer. Target Oncol. 15, 163–174 (2020).
39. Chen, D., Wei, L., Yu, J. & Zhang, L. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin. Cancer Res. 20, 3472–3484 (2014).
40. Tarantelli, C. et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Adv. 4, 819–829 (2020).
41. Schneider, P. et al. The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro. Exp. Dermatol. 23, 579–584 (2014).
42. Liu, N. et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12, 2319–2330 (2013).
43. Roulston, A., Muller, W. J. & Shore, G. C. BIM, PUMA, and the achilles’ heel of oncogene addiction. Sci. Signal. 6, pe12 (2013).
44. Yu, J. & Zhang, L. PUMA, a potent killer with or without p53. Oncogene 27, 571–583 (2008).
45. Chipuk, J. E. & Green, D. R. PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 8, 2690–2696 (2009).
46. Westphal, D., Dewson, G., Czabotar, P. E. & Kluck, R. M. Molecular biology of Bax and Bak activation and action. Biochim. Biophys. Acta 1813, 521–531 (2011).
47. Sun, J. et al. The multi-targeted kinase inhibitor suitinib induces apoptosis in colon cancer cells via PUMA. PLoS ONE 7, e43158 (2012).
48. Wong, R. S. Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res. 30, 87 (2011).
49. Carneiro, B. A. & El-Deiry, W. S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 17, 395–341 (2020).